Work

Concepts and Controversies in Eosinophilic Esophagitis: What’s Coming Down the Pipe?

Year: 2023

Type: article

Source: Gastroenterology

DOI: 10.1053/j.gastro.2023.10.035

Authors: Kathryn Peterson, Margaret H. Collins, Seema S. Aceves, Mirna Chehade, Nirmala Gonsalves

Institutions: University of Utah, Cincinnati Children's Hospital Medical Center, University of Cincinnati, University of California San Diego, Rady Children's Hospital-San Diego, Icahn School of Medicine at Mount Sinai, Northwestern University

Language: English

Topic: Eosinophilic Esophagitis

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Bristol-Myers Squibb, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Celgene, Danone, American Partnership for Eosinophilic Disorders, Regeneron Pharmaceuticals, Celldex Therapeutics, Rare Diseases Clinical Research Network, Eosinophilic Family Coalition, National Institutes of Health, University of California, San Diego, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, National Center for Advancing Translational Sciences

Awards: G1213946416, G1470677290, G2976362549, Relationship of Immune Responses to Clinical Phenotype and Familial Risk in Eosinophilic Gastroenteritis, G4279768677, G481745248, G4913822037, G9000004606, G9000297893, G9000318819, Data Management and Coordinating Center: Rare Diseases Clinical Research Network, G947216580

OpenAlex ID: W4389285442

FWCI: 0.474

Cites: 33

Cited by: 2

Related to: 10